US Archives - Page 45 of 100 - European Medical Journal

Hidradenitis Suppurativa Long-Term Data Shows Lasting Relief

Long-term data reveal that bimekizumab, a dual IL-17A and IL-17F inhibitor, provides sustained symptom control for patients with hidradenitis suppurativa (HS).

What Do Brain Oscillations Tell Us About Epilepsy in Alzheimer’s?

High-frequency oscillations (HFOs) as potential biomarkers in Alzheimer’s disease (AD), have been highlighted in a new study, offering insight into how epilepsy affects neurodegeneration.

Long-Term Study on Effects of IVF on Cancer Risk

A long-term study of assisted reproductive technology (ART) has found no increased risk of endometrial cancer, addressing concerns about the potential long-term effects of fertility treatments.

A Roadmap for Clear Skin

Notable recent additions to dermatologists’ acne toolkit include newer dual and triple combination therapies, as well as agents with…

AMJ Dermatology 2 [Supplement 1] 2025

Notable recent additions to dermatologists’ acne toolkit include newer dual and triple combination therapies, as well as agents with…

New Clinical Guidelines for Managing Central Airway Obstruction

Clinical practice guidelines providing critical recommendations for managing central airway obstruction (CAO), a condition linked to poor prognosis in both malignant and nonmalignant airway diseases, have recently been published.

What Are Best Next Steps After JAKi Failure?

For patients with rheumatoid arthritis (RA) with an inadequate response to Janus kinase inhibitors (JAKi), new research suggests that cycling to another JAKi may be more effective than switching to a biologic disease-modifying anti-rheumatic drug (bDMARD).

Statins Linked to Better Immune Checkpoint Inhibitor Outcomes

A recent meta-analysis suggests that statin use is associated with improved survival outcomes in patients with cancer undergoing immune checkpoint inhibitor (ICI) therapy.

Twice-Yearly HIV Prevention Shot Nears FDA Decision

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for the first-ever twice-yearly injectable HIV prevention therapy.

New Therapy Hope for Hard-to-Treat DLBCL

A new treatment combination has emerged for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT).